Regulatory restrictions on the use of valproate in girls and women of childbearing potential: status update

Abstract

In 2019, some restrictions for use of valproic acid in women with reproductive potential by regulatory authorities and the original drug manufacturer based on the results of studies in real clinical practice were introduced. During 2019–2021, there were a further clinical data accumulation and labeling changes. The review presents a critical analysis of the changes in prescribing information and product label. There is a long lead time from the moment when safety data become known to the moment when changes are made to the medicinal product label and patient brochures. Some of the changes, including the need for high doses of folic acid to prevent neural tube defects, are debatable. Repealing the provision for mandatory archiving of informed consent forms for valproic acid use in girls and women raises legal risks. Improvements in pregnancy prevention programs and further research on the safety of valproic acid in real-world clinical settings are needed.

Keywords

• epilepsy
• pregnancy
• teratogenicity
• serious birth defects
• attention deficit and hyperactivity disorder
• adhd
• autism
• autism spectrum disorders
• asds
• valproic acid
• valproate
• hearing impairment
• hearing loss
• male fertility disorders
• pregnancy prevention program